Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Uridine monophosphate (UMP) has garnered some scientific interest as a potential cognitive enhancer, including for the support or treatment of poor concentration. UMP is a nucleotide involved in the synthesis of RNA and the modulation of neuronal membrane phospholipids. Preclinical studies—primarily in rodents—suggest that UMP, especially in combination with other compounds like choline and DHA (docosahexaenoic acid), may enhance synaptic membrane synthesis and support neurotransmitter function, which could theoretically benefit cognitive processes such as attention and concentration. A few small-scale human studies have investigated uridine-containing supplements for cognitive function, typically in the context of age-related cognitive decline or Alzheimer’s disease. For example, a 2017 randomized controlled trial found modest improvements in certain cognitive domains in patients with mild Alzheimer’s who took a medical food containing uridine, choline, and DHA. However, evidence specifically linking UMP supplementation to improved concentration in healthy individuals or those with attention deficits is limited and indirect. Overall, while the biological plausibility exists and preliminary research is promising, the direct evidence supporting UMP for improving concentration in humans is weak and mostly extrapolated from animal research or studies with confounding variables. Thus, the evidence rating is 2 out of 5—suggesting early scientific validation but insufficient high-quality clinical evidence for this specific use.

More about Uridine monophosphate
More about Concentration (poor)

Other ingredients used for Concentration (poor)

Other health conditions supported by Uridine monophosphate

Products containing Uridine monophosphate